TDNA
T. Rowe Price Biotech ETF
1W: +0.4%
YTD: -3.6%
$24.57
-0.48 (-1.93%)
Overview
Chart
Holdings
Changes
Technicals
Analysis
Peers
Institutions
Dark Pool
Short Interest
Dividends
Weather
Portfolio Health Summary
IS Overall Score
47.5
★★★★★
Altman Z-Score
24.25
Safe
Weight Coverage
97%
of portfolio analyzed
Holdings Matched
82
with fundamental data
InsiderStreet Scorecard
★★★★★
47.5
Top Holdings: Score Breakdown
Risk & Quality Signals
Altman Z-Score
24.25
Safe Zone (>2.99)
Piotroski F-Score
3.6 / 9
Weak
Beneish M-Score
0.08
Possible Manipulator
Credit Score
—
Earnings Quality
49.3 / 100
Portfolio Valuation
P/E
45.92x
P/B
8.04x
P/S
10.00x
EV/EBITDA
36.20x
EV/Revenue
10.13x
P/FCF
41.16x
P/OCF
36.74x
PEG
5.76x
Earnings Yield
2.18%
FCF Yield
2.43%
OCF Yield
2.72%
Median P/E
-11.91x
Growth & Shareholder Returns
Year-over-Year Growth
Revenue
+57.3%
Net Income
-1.7%
EPS
+9.9%
FCF
+2.4%
EBITDA
+4.9%
Op. Income
—
Compound Growth Rates
Rev CAGR 3Y
+72.1%
Rev CAGR 5Y
+41.8%
EPS CAGR 3Y
+8.0%
EPS CAGR 5Y
+13.9%
FCF CAGR 3Y
+20.4%
FCF CAGR 5Y
+16.7%
EBITDA CAGR 3Y
+1.6%
EBITDA CAGR 5Y
+13.9%
Payout Ratio
2.89%
Buyback Yield
0.39%
Dividend Yield
0.05%
Total Shareholder Return
-5.28%
Earnings Stability
All Ratios & Metrics
Valuation (12)
| Metric | Value |
|---|---|
| Portfolio P/E | 45.92 |
| Portfolio P/B | 8.04 |
| Portfolio P/S | 10.00 |
| EV/EBITDA | 36.20 |
| EV/Revenue | 10.13 |
| P/FCF | 41.16 |
| P/OCF | 36.74 |
| PEG | 5.76 |
| Earnings Yield | 2.18% |
| FCF Yield | 2.43% |
| OCF Yield | 2.72% |
| Median P/E | -11.91 |
Profitability & Returns (9)
| Metric | Value |
|---|---|
| Gross Margin | 80.22% |
| Operating Margin | 3.91% |
| Net Margin | 3.45% |
| FCF Margin | 11.52% |
| ROE | 3.01% |
| ROA | 1.64% |
| ROIC | 6.57% |
| ROCE | — |
| Asset Turnover | — |
Leverage & Solvency (6)
| Metric | Value |
|---|---|
| Debt/Equity | 0.47 |
| Debt/Assets | 0.25 |
| Net Debt/EBITDA | -0.75 |
| Interest Coverage | 2.19 |
| Current Ratio | 3.05 |
| Quick Ratio | 2.79 |
Efficiency (4)
| Metric | Value |
|---|---|
| Asset Turnover | — |
| Inventory Turnover | — |
| Receivables Turnover | — |
| Payables Turnover | — |
Growth — YoY (6)
| Metric | Value |
|---|---|
| Revenue Growth | 57.30% |
| Net Income Growth | -1.67% |
| EPS Growth | 9.90% |
| FCF Growth | 2.36% |
| EBITDA Growth | 4.91% |
| Op. Income Growth | — |
Growth — CAGR (16)
| Metric | Value |
|---|---|
| Revenue CAGR 3Y | 72.08% |
| Revenue CAGR 5Y | 41.81% |
| Revenue CAGR 10Y | — |
| EPS CAGR 3Y | 7.97% |
| EPS CAGR 5Y | 13.92% |
| EPS CAGR 10Y | — |
| FCF CAGR 3Y | 20.41% |
| FCF CAGR 5Y | 16.66% |
| FCF CAGR 10Y | — |
| EBITDA CAGR 3Y | 1.60% |
| EBITDA CAGR 5Y | 13.88% |
| EBITDA CAGR 10Y | — |
| Net Income CAGR 3Y | 6.37% |
| Net Income CAGR 5Y | 12.78% |
| Op. Income CAGR 3Y | — |
| Op. Income CAGR 5Y | — |
Quality Scores (13)
| Metric | Value |
|---|---|
| IS Overall | 47.5 |
| IS Profitability | 38.9 |
| IS Balance Sheet | 56.8 |
| IS Earnings Quality | 49.3 |
| IS Growth | 57.3 |
| IS Value | 35.4 |
| IS Momentum | 60.3 |
| IS Safety | 85.2 |
| IS Quality | 52.9 |
| Altman Z-Score | 24.25 |
| Piotroski F-Score | 3.65 |
| Beneish M-Score | 0.08 |
| Credit Score | — |
Dividends & Payout (4)
| Metric | Value |
|---|---|
| Dividend Yield | 0.05% |
| Payout Ratio | 2.89% |
| Buyback Yield | 0.39% |
| Total Shareholder Return | -5.28% |
Growth Stability (4)
| Metric | Value |
|---|---|
| Revenue Stability | 0.696 |
| Earnings Stability | 0.554 |
| Earnings Persistence | 0.694 |
| Margin Stability | 0.576 |
Medians (3)
| Metric | Value |
|---|---|
| Median P/E | -11.91 |
| Median P/B | 4.83 |
| Median Dividend Yield | — |
Coverage Meta (3)
| Metric | Value |
|---|---|
| Weight Coverage % | 97.46% |
| Holdings Matched | 82 |
| Total Holdings | 86 |